{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:38:26Z","timestamp":1740166706000,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das Vorliegen einer thrombotisch-thrombozytopenischen Purpura\u00a0(TTP) als Kombination aus Thrombozytopenie, LDH-Erh\u00f6hung und An\u00e4mie in Kombination mit einer Organbeteiligung ist eine seltene, aber lebensbedrohliche Erkrankung, die unbehandelt mit einer extrem hohen Letalit\u00e4t in der Akutphase einhergeht. Wir stellen in dem vorliegenden Beitrag den Fall einer 49-j\u00e4hrigen Patientin vor, die mit unklaren abdominellen Beschwerden und subfebrilen Temperaturen station\u00e4r aufgenommen wurde, und leiten daraus Empfehlungen f\u00fcr die Notfallsituation ab. Ein erh\u00f6htes Bewusstsein f\u00fcr die Erkrankung und die zielgerichtete weiterf\u00fchrende Diagnostik mit Bestimmung des PLASMIC-Scores bzw. der ADAMTS13-Aktivit\u00e4t f\u00fchrt ggf. direkt zur TTP, deren verz\u00f6gerte Diagnostik regelhaft zu Sekund\u00e4rkomplikationen f\u00fchren w\u00fcrde.<\/jats:p>","DOI":"10.1007\/s00063-022-00982-w","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:03:27Z","timestamp":1672841007000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thrombotisch-thrombozytopenische Purpura\u00a0\u2013 eine differenzialdiagnostische Herausforderung im Notfall","Thrombotic thrombocytopenic purpura\u2014a\u00a0differential diagnostic challenge in an emergency"],"prefix":"10.1007","volume":"118","author":[{"given":"Fedai","family":"\u00d6zcan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"K\u00f6hrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirak","family":"Petros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg Christian","family":"Brokmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"4","key":"982_CR1","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi\u00a0PK, Hurwitz\u00a0S, Fry\u00a0A, Marques\u00a0MB, Waldo\u00a0SW, Li\u00a0A, Sun\u00a0L, Upadhyay\u00a0V, Hamdan\u00a0A, Brunner\u00a0AM et\u00a0al (2017) Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a\u00a0cohort study. Lancet Haematol 4(4):e157\u2013e164","journal-title":"Lancet Haematol"},{"issue":"1","key":"982_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jth.13882","volume":"16","author":"A Li","year":"2018","unstructured":"Li\u00a0A, Khalighi\u00a0PR, Wu\u00a0Q, Garcia\u00a0DA (2018) External validation of the PLASMIC score: a\u00a0clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J\u00a0Thromb Haemost 16(1):164\u2013169","journal-title":"J Thromb Haemost"},{"issue":"3","key":"982_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully\u00a0M, Hunt\u00a0BJ, Benjamin\u00a0S, Liesner\u00a0R, Rose\u00a0P, Peyvandi\u00a0F, Cheung\u00a0B, Machin\u00a0SJ, British Committee for Standards in H (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158(3):323\u2013335","journal-title":"Br J Haematol"},{"issue":"11","key":"982_CR4","first-page":"1194","volume":"86","author":"G Meloni","year":"2001","unstructured":"Meloni\u00a0G, Proia\u00a0A, Antonini\u00a0G, De Lena\u00a0C, Guerrisi\u00a0V, Capria\u00a0S, Trisolini\u00a0SM, Ferrazza\u00a0G, Sideri\u00a0G, Mandelli\u00a0F (2001) Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation. Haematologica 86(11):1194\u20131199","journal-title":"Haematologica"},{"issue":"9","key":"982_CR5","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1538-7836.2012.04852.x","volume":"10","author":"RS Camilleri","year":"2012","unstructured":"Camilleri\u00a0RS, Scully\u00a0M, Thomas\u00a0M, Mackie\u00a0IJ, Liesner\u00a0R, Chen\u00a0WJ, Manns\u00a0K, Machin\u00a0SJ (2012) A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J\u00a0Thromb Haemost 10(9):1792\u20131801","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"982_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","volume":"9","author":"Y Fujimura","year":"2011","unstructured":"Fujimura\u00a0Y, Matsumoto\u00a0M, Isonishi\u00a0A, Yagi\u00a0H, Kokame\u00a0K, Soejima\u00a0K, Murata\u00a0M, Miyata\u00a0T (2011) Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J\u00a0Thromb Haemost 9(Suppl 1):283\u2013301","journal-title":"J Thromb Haemost"},{"issue":"1","key":"982_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood-2005-06-2482","volume":"107","author":"B Plaimauer","year":"2006","unstructured":"Plaimauer\u00a0B, Fuhrmann\u00a0J, Mohr\u00a0G, Wernhart\u00a0W, Bruno\u00a0K, Ferrari\u00a0S, Konetschny\u00a0C, Antoine\u00a0G, Rieger\u00a0M, Scheiflinger\u00a0F (2006) Modulation of ADAMTS13 secretion and specific activity by a\u00a0combination of common amino acid polymorphisms and a\u00a0missense mutation. Blood 107(1):118\u2013125","journal-title":"Blood"},{"issue":"11","key":"982_CR8","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","volume":"103","author":"XL Zheng","year":"2004","unstructured":"Zheng\u00a0XL, Kaufman\u00a0RM, Goodnough\u00a0LT, Sadler\u00a0JE (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103(11):4043\u20134049","journal-title":"Blood"},{"issue":"6","key":"982_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock\u00a0GA, Shumak\u00a0KH, Buskard\u00a0NA, Blanchette\u00a0VS, Kelton\u00a0JG, Nair\u00a0RC, Spasoff\u00a0RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N\u00a0Engl J Med 325(6):393\u2013397","journal-title":"N Engl J Med"},{"issue":"1","key":"982_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","volume":"82","author":"P Coppo","year":"2003","unstructured":"Coppo\u00a0P, Bussel\u00a0A, Charrier\u00a0S, Adrie\u00a0C, Galicier\u00a0L, Boulanger\u00a0E, Veyradier\u00a0A, Leblanc\u00a0T, Alberti\u00a0C, Azoulay\u00a0E et al (2003) High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome. Medicine 82(1):27\u201338","journal-title":"Medicine"},{"issue":"19","key":"982_CR11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","volume":"130","author":"M Scully","year":"2017","unstructured":"Scully\u00a0M, Knobl\u00a0P, Kentouche\u00a0K, Rice\u00a0L, Windyga\u00a0J, Schneppenheim\u00a0R, Kremer Hovinga\u00a0JA, Kajiwara\u00a0M, Fujimura\u00a0Y, Maggiore\u00a0C et al (2017) Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood 130(19):2055\u20132063","journal-title":"Blood"},{"issue":"4","key":"982_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully\u00a0M, Cataland\u00a0SR, Peyvandi\u00a0F, Coppo\u00a0P, Knobl\u00a0P, Kremer Hovinga\u00a0JA, Metjian\u00a0A, de la Rubia\u00a0J, Pavenski\u00a0K, Callewaert\u00a0F et\u00a0al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N\u00a0Engl J Med 380(4):335\u2013346","journal-title":"N Engl J Med"},{"issue":"6","key":"982_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi\u00a0F, Scully\u00a0M, Kremer Hovinga\u00a0JA, Cataland\u00a0S, Knobl\u00a0P, Wu\u00a0H, Artoni\u00a0A, Westwood\u00a0JP, Mansouri Taleghani\u00a0M, Jilma\u00a0B et\u00a0al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N\u00a0Engl J Med 374(6):511\u2013522","journal-title":"N Engl J Med"},{"issue":"20","key":"982_CR14","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","volume":"116","author":"JN George","year":"2010","unstructured":"George\u00a0JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116(20):4060\u20134069","journal-title":"Blood"},{"issue":"1","key":"982_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"A Froissart","year":"2012","unstructured":"Froissart\u00a0A, Buffet\u00a0M, Veyradier\u00a0A, Poullin\u00a0P, Provot\u00a0F, Malot\u00a0S, Schwarzinger\u00a0M, Galicier\u00a0L, Vanhille\u00a0P, Vernant\u00a0JP et al (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a\u00a0suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40(1):104\u2013111","journal-title":"Crit Care Med"},{"issue":"3","key":"982_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","volume":"136","author":"M Scully","year":"2007","unstructured":"Scully\u00a0M, Cohen\u00a0H, Cavenagh\u00a0J, Benjamin\u00a0S, Starke\u00a0R, Killick\u00a0S, Mackie\u00a0I, Machin\u00a0SJ (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a\u00a0reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136(3):451\u2013461","journal-title":"Br J Haematol"},{"issue":"19","key":"982_CR17","first-page":"327","volume":"115","author":"M Bommer","year":"2018","unstructured":"Bommer\u00a0M, Wolfle-Guter\u00a0M, Bohl\u00a0S, Kuchenbauer\u00a0F (2018) The differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int 115(19):327\u2013334","journal-title":"Dtsch Arztebl Int"},{"issue":"13","key":"982_CR18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","volume":"137","author":"T Dutt","year":"2021","unstructured":"Dutt\u00a0T, Shaw\u00a0RJ, Stubbs\u00a0M, Yong\u00a0J, Bailiff\u00a0B, Cranfield\u00a0T, Crowley\u00a0MP, Desborough\u00a0M, Eyre\u00a0TA, Gooding\u00a0R et al (2021) Real-world experience with caplacizumab in the management of acute TTP. Blood 137(13):1731\u20131740","journal-title":"Blood"},{"issue":"13","key":"982_CR19","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","volume":"4","author":"LA Volker","year":"2020","unstructured":"Volker\u00a0LA, Kaufeld\u00a0J, Miesbach\u00a0W, Brahler\u00a0S, Reinhardt\u00a0M, Kuhne\u00a0L, Muhlfeld\u00a0A, Schreiber\u00a0A, Gaedeke\u00a0J, Tolle\u00a0M et al (2020) Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv 4(13):3085\u20133092","journal-title":"Blood Adv"},{"issue":"6","key":"982_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo\u00a0P, Bubenheim\u00a0M, Azoulay\u00a0E, Galicier\u00a0L, Malot\u00a0S, Bige\u00a0N, Poullin\u00a0P, Provot\u00a0F, Martis\u00a0N, Presne\u00a0C et al (2021) A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137(6):733\u2013742","journal-title":"Blood"},{"issue":"11","key":"982_CR21","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/jth.15045","volume":"18","author":"LA Volker","year":"2020","unstructured":"Volker\u00a0LA, Brinkkoetter\u00a0PT, Knobl\u00a0PN, Krstic\u00a0M, Kaufeld\u00a0J, Menne\u00a0J, Buxhofer-Ausch\u00a0V, Miesbach\u00a0W (2020) Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. J\u00a0Thromb Haemost 18(11):3061\u20133066","journal-title":"J Thromb Haemost"},{"issue":"1","key":"982_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1905426","volume":"381","author":"DP Chander","year":"2019","unstructured":"Chander\u00a0DP, Loch\u00a0MM, Cataland\u00a0SR, George\u00a0JN (2019) Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura. N\u00a0Engl J Med 381(1):92\u201394","journal-title":"N Engl J Med"},{"key":"982_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11560-021-00487-1","volume":"16","author":"A G\u00e4ckler","year":"2021","unstructured":"G\u00e4ckler\u00a0A, Witzke\u00a0O (2021) Thrombotische Mikroangiopathie\u00a0\u2013 Diagnose und Therapie. Nephrologe 16:113\u2013123","journal-title":"Nephrologe"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-022-00982-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-022-00982-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-022-00982-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T08:02:34Z","timestamp":1683187354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-022-00982-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s00063-022-00982-w","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"type":"print","value":"2193-6218"},{"type":"electronic","value":"2193-6226"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Erstellung dieses Beitrags wurde von der Firma Sanofi mit einem Educational Grant finanziell unterst\u00fctzt. Eine Pr\u00fcfung und Freigabe des Artikels durch die Firma erfolgten nicht. Die Autoren F.\u00a0\u00d6zcan, M.\u00a0K\u00f6hrmann, S.\u00a0Petros, A.\u00a0Goette, P.\u00a0Bramlage, M.\u00a0Bommer und J.C.\u00a0Brokmann erkl\u00e4ren, dass Sie unabh\u00e4ngig von der Erstellung des Artikels, von Sanofi Honorare f\u00fcr die Teilnahme an Advisory Boards und\/oder Vortr\u00e4ge und\/oder Pr\u00e4sentationen und\/oder Fortbildungsveranstaltungen erhalten haben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}